Stockwinners Market Radar for October 28, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

13:50 EDT Celgene Ozanimod demonstrates superiority versus Biogen Avonex - Celgene (CELG) has announced detailed results from the phase III RADIANCE Part B trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator, versus a first-line treatment, Biogen's (BIIB) Avonex, in patients with relapsing multiple sclerosis. The results were presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting. The RADIANCE Part B study evaluated two doses of oral ozanimod compared with IFN in 1,320 patients with RMS in 21 countries treated for two years. A significant reduction in annualized relapse rate was demonstrated for ozanimod 1 mg and for ozanimod 0.5 mg compared with IFN over two years of treatment. A significant reduction in new or enlarging T2 lesions was demonstrated for ozanimod 1 mg and 0.5 mg compared with IFN. A significant reduction in gadolinium-enhanced MRI lesions was also demonstrated for ozanimod 1 mg and ozanimod 0.5 mg compared with IFN. In RADIANCE Part B, a reduction in brain volume loss, a measure associated with MS disease progression, was observed for both ozanimod doses compared with IFN. Whole brain volume loss was reduced by 27% with the 1 mg dose of ozanimod and by 25% in the 0.5 mg group versus IFN at two years. In a pre-specified pooled analysis of the SUNBEAM and RADIANCE Part B studies, ozanimod did not reach statistical significance compared with IFN in the time to 3-month confirmed disability progression. A very low rate of disability progression was observed across all treatment groups. Treatment-emergent adverse events were experienced by 75% of patients on ozanimod 1 mg, 74 percent on ozanimod 0.5 mg and 83% on IFN. Most AEs were mild; the most common AEs across all treatment groups were nasopharyngitis, headache, alanine aminotransferase increased, influenza-like illness, hypertension, gamma-glutamyl transferase increased, pharyngitis and urinary tract infection. AEs of alanine aminotransferase increased were low, transient and generally resolved without study drug discontinuation. The overall safety and tolerability profile was consistent with results from the previously reported phase II RADIANCE Part A and phase III SUNBEAM studies in RMS.

13:32 EDT Buenaventura CFO Carlos Galvez retires, Leandro Garcia to succeed - Buenaventura has announced the retirement of Carlos Galvez, Vice President and CFO, after almost forty years with the company. Leandro Garcia, Buenaventura's Controller, will succeed Galvez as Vice President and CFO effective December 1, 2017, to lead Buenaventura's financial, commercial and administrative departments.